For the Inventor, By the Inventor

Enter assignee name

Waltham, MA, United States of America

Immunogen, Inc.

USPTO Granted Patents = 256

% Expired Patents = 32.4

CIPO Patents = 21

EPO Patents = 70

Trademarks = 11

Forward Citations = 6,696

Loading Chart...

Loading Chart...

132 inventors (with patents filed for the assignee):

Ravi V J Chari (90 out of 94 patents)

Michael Louis Miller (53 out of 57 patents)

Daniel J Tavares (43 out of 54 patents)

4. Wayne Charles Widdison (40 out of 40 patents)

5. Robert Yongxin Zhao (35 out of 59 patents)

6. Lingyun Rui (28 out of 36 patents)

7. Wei Li (27 out of 37 patents)

8. Manami Shizuka (24 out of 30 patents)

9. Nathan Elliott Fishkin (23 out of 28 patents)

10. Richard A Silva (21 out of 27 patents)

11. Rajeeva Singh (21 out of 21 patents)

12. Olga Ab (20 out of 20 patents)

13. Gillian Payne (18 out of 19 patents)

14. Viktor S Goldmakher (17 out of 20 patents)

15. Thomas D Chittenden (17 out of 20 patents)

Core Competencies:

Antibody Conjugates

Cytotoxic Benzodiazepines

Maytansinoid Derivatives

Immunoconjugates

Folate Receptor 1

Therapeutic Combinations

Cell-Binding Agents

Diagnostic Assays

Peptide Linkers

Cross-Linkers

Cancer Therapy

Purification Methods

256 patents: Sort by Forward Citations

1. 12747250 - CAMPTOTHECIN DERIVATIVES (2026-09-29),

2. 12390471 - Maytansinoid derivatives with self-immolative peptide linkers and conjugates thereof (2025-08-19),

3. 11981688 - Methods of preparing cytotoxic benzodiazepine derivatives (2024-05-14),

4. 11981687 - Methods of preparing cytotoxic benzodiazepine derivatives (2024-05-14),

5. RE49918 - Cytotoxic benzodiazepine derivatives (2024-04-16),

6. 11945862 - Compositions and methods for antibody production (2024-04-02),

7. 11932701 - Method for increasing the efficacy of cancer therapy by administering an anti-FOLR1 immunoconjugate (2024-03-19),

8. 11897961 - Anti-CD123 antibodies and conjugates and derivatives thereof (2024-02-13),

9. 11834498 - Biparatopic FR-alpha antibodies and immunoconjugates (2023-12-05),

10. 11833214 - Methods of preparing cell-binding agent-drug conjugates (2023-12-05),

11. 11793885 - Substituted benzo[5,6][1,4]diazepino[1,2-a]indoles for the treatment of proliferative disorders (2023-10-24),

12. 11760759 - Process for preparing substituted indolines (2023-09-19),

13. 11744900 - Preparation of maytansinoid antibody conjugates by a one-step process (2023-09-05),

14. 11732038 - Conjugates comprising cell-binding agents and cytotoxic agents (2023-08-22),

15. 11701428 - Therapeutic combinations comprising anti-CD123 immunoconjugates (2023-07-18),

Company Overview

Immunogen, Inc., based in Waltham, MA, specializes in the development of antibody-drug conjugates (ADCs) for cancer treatment. The company focuses on innovative therapeutic solutions that leverage its expertise in cytotoxic benzodiazepines and maytansinoid derivatives. Immunogen's research encompasses a range of core technologies, including immunoconjugates and cell-binding agents, aimed at enhancing the efficacy of cancer therapies while minimizing side effects. Their commitment to advancing targeted therapies positions them as a key player in the oncology field.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 13 2026

256 Patents

#9 in Waltham, MA

#100 in Massachusetts

#1,680 in US

#3,412 in the World

Waltham, MA, United States of America

Immunogen, Inc.

Forward Citations = 6,696

132 inventors:

Ravi V J Chari (90 out of 94 patents)

Michael Louis Miller (53 out of 57 patents)

Daniel J Tavares (43 out of 54 patents)

4. Wayne Charles Widdison (40 out of 40 patents)

5. Robert Yongxin Zhao (35 out of 59 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Immunogen, Inc.. Retrieved from https://idiyas.com/company/immunogen

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…